(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Jasgit Sachdev, MD
IDEAYA Biosciences
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
18 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- St. Vincent'S Health Sydney
Sydney, New South Wales, Australia
- Alfred Health
Melbourne, Victoria, Australia
- Princess Margaret Cancer Centre
Toronto, Ontario, Canada
- Institute Curie
Paris, France
- Charité - Universitätsmedizin Berlin
Berlin, Germany
- Fondazione Irccs Istituto Nazionale Tumori
Milan, Italy
- Fondazione Policlinico Universitario Agostino Gemelli Irccs
Rome, Italy
- Leiden University Medical Center
Leiden, Netherlands
- Honorhealth Research Institute
Scottsdale, Arizona, United States
- Moores Cancer Center
La Jolla, California, United States
- Stanford Cancer Institute
Palo Alto, California, United States
- University of Miami
Miami, Florida, United States
- the Cancer and Hematology Centers
Grand Rapids, Michigan, United States
- Mayo Clinic Rochester
Rochester, Minnesota, United States
- Northwell
Manhasset, New York, United States
- Thomas Jefferson University
Philadelphia, Pennsylvania, United States
- Sarah Cannon Research Institute
Nashville, Tennessee, United States
- University of Texas Southwestern Medical Center
Dallas, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 3 Jul 2023
- Primary completion
- 30 Apr 2027
- Completion
- 30 Apr 2030
- Last update posted
- 16 Mar 2026
- Registered enrollment
- 160
- Registry id
- NCT05907954
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.